Effectiveness of Fimasartan and Rosuvastatin Combination Treatment in Hypertensive Patients With Dyslipidemia
The goal of this study was to evaluate the concurrent control rate of hypertension and dyslipidemia by fimasartan and rosuvastatin in patients who were concomitantly prescribed both drugs. : This single-center, cross-sectional study was conducted in 536 patients with hypertension and dyslipidemia wh...
Gespeichert in:
| Veröffentlicht in: | Clinical therapeutics 2020-06, Vol.42 (6), p.1058-1066.e3 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1066.e3 |
|---|---|
| container_issue | 6 |
| container_start_page | 1058 |
| container_title | Clinical therapeutics |
| container_volume | 42 |
| creator | Lee, Seung-Jun Oh, Jaewon Hong, Sung-Jin Cho, In-Jeong Kim, Su Rae Uhm, Jae-Sun Shim, Chi Young Chang, Hyuk-Jae Ahn, Chul-Min Kim, Jung-Sun Kim, Byeong-Keuk Park, Sungha Lee, Sang-Hak Hong, Geu Ru Ko, Young-Guk Choi, Donghoon |
| description | The goal of this study was to evaluate the concurrent control rate of hypertension and dyslipidemia by fimasartan and rosuvastatin in patients who were concomitantly prescribed both drugs.
: This single-center, cross-sectional study was conducted in 536 patients with hypertension and dyslipidemia who were taking fimasartan and rosuvastatin together for at least 12 weeks. Patients were enrolled from October 2016 to March 2018 at a tertiary hospital in the Republic of Korea. The primary end point was the concurrent control rate of blood pressure ( |
| doi_str_mv | 10.1016/j.clinthera.2020.03.019 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2399831731</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0149291820301867</els_id><sourcerecordid>2425657464</sourcerecordid><originalsourceid>FETCH-LOGICAL-c394t-ead5247d39b826a29369bbe397b411ef3467f7f01be28c03b36a2d4dd8279763</originalsourceid><addsrcrecordid>eNqFkU9rHCEYh6U0NNs0X6EVeullJv5bHY9hkzSFQEtZaG7ijO8QlxndqrOw376GTXPopSdFn_en_B6EPlHSUkLl1a4dJh_KEyTbMsJIS3hLqH6DVrRTuqFUPL5FK0KFbpim3Tl6n_OOEML1mr1D55xxJQmXKzTfjiMMxR8gQM44jvjOzzbbVGzANjj8M-blYHOxxQe8iXPvQ93GgLcJbJkhFFwv7o97SAVCrkH4RwXqeca_fHnCN8c8-b13MHv7AZ2Ndspw-bJeoO3d7XZz3zx8__ptc_3QDFyL0oB1ayaU47rvmLRMc6n7HrhWvaAURi6kGtVIaA-sGwjveYWccK5jSivJL9CXU-w-xd8L5GJmnweYJhsgLtkwrnXHqeK0op__QXdxSaF-zjDB1nKthBSVUidqSDHnBKPZp1pTOhpKzLMQszOvQsyzEEO4qULq5MeX_KWfwb3O_TVQgesTALWPg4dk8lDbG8D5VMUYF_1_H_kDZX2h8A</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2425657464</pqid></control><display><type>article</type><title>Effectiveness of Fimasartan and Rosuvastatin Combination Treatment in Hypertensive Patients With Dyslipidemia</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Lee, Seung-Jun ; Oh, Jaewon ; Hong, Sung-Jin ; Cho, In-Jeong ; Kim, Su Rae ; Uhm, Jae-Sun ; Shim, Chi Young ; Chang, Hyuk-Jae ; Ahn, Chul-Min ; Kim, Jung-Sun ; Kim, Byeong-Keuk ; Park, Sungha ; Lee, Sang-Hak ; Hong, Geu Ru ; Ko, Young-Guk ; Choi, Donghoon</creator><creatorcontrib>Lee, Seung-Jun ; Oh, Jaewon ; Hong, Sung-Jin ; Cho, In-Jeong ; Kim, Su Rae ; Uhm, Jae-Sun ; Shim, Chi Young ; Chang, Hyuk-Jae ; Ahn, Chul-Min ; Kim, Jung-Sun ; Kim, Byeong-Keuk ; Park, Sungha ; Lee, Sang-Hak ; Hong, Geu Ru ; Ko, Young-Guk ; Choi, Donghoon</creatorcontrib><description>The goal of this study was to evaluate the concurrent control rate of hypertension and dyslipidemia by fimasartan and rosuvastatin in patients who were concomitantly prescribed both drugs.
: This single-center, cross-sectional study was conducted in 536 patients with hypertension and dyslipidemia who were taking fimasartan and rosuvastatin together for at least 12 weeks. Patients were enrolled from October 2016 to March 2018 at a tertiary hospital in the Republic of Korea. The primary end point was the concurrent control rate of blood pressure (<140/90 mm Hg) and LDL-C. As a secondary end point, the target blood pressure <130/80 mm Hg was adopted in all patients or in high-risk patients with atherosclerotic cardiovascular diseases. Target LDL-C and non–HDL-C levels followed the domestic guidelines. Correlation between blood pressure control and lipid profile was also evaluated. All parameters were assessed in a clinic by board-certified physicians.
Of the total 536 patients, 69% (n = 368) had very high (n = 308) or high (n = 60) cardiovascular risk, with an average age of 65 years; 57% were male. When the target blood pressure was set at 140/90 mm Hg, the proportion of patients meeting the targeting LDL-C level was 40.3% (95% CI, 36.2–44.5; P < 0.001). When applied to the revised blood pressure criteria targeting 130/80 mm Hg, the concurrent control rate dropped by one half to 20.3% (95% CI, 17.2–24.0; P < 0.001). To apply the new blood pressure criteria, more intensive management is mandatory in patients with high or very high cardiovascular risk. There was no positive correlation between the controlled rate of hypertension and dyslipidemia.
Fimasartan and rosuvastatin were shown to have effects on target diseases, but there was no synergistic effect when administered in combination. The higher the cardiovascular risk of the patients, the lower the rate of concurrent control when fimasartan and rosuvastatin were administered simultaneously. More active treatment is therefore required in high-risk patients.</description><identifier>ISSN: 0149-2918</identifier><identifier>EISSN: 1879-114X</identifier><identifier>DOI: 10.1016/j.clinthera.2020.03.019</identifier><identifier>PMID: 32376036</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject><![CDATA[Adult ; Aged ; angiotensin receptor blocker ; Anticholesteremic Agents - administration & dosage ; Antihypertensive Agents - administration & dosage ; Antihypertensives ; Arteriosclerosis ; Atherosclerosis ; Biphenyl Compounds - administration & dosage ; Blood pressure ; Blood Pressure - drug effects ; Cardiovascular disease ; Cardiovascular diseases ; Cholesterol ; Cholesterol, LDL - blood ; Clinical medicine ; Coronary vessels ; Cross-Sectional Studies ; Drug dosages ; Drug Therapy, Combination ; Dyslipidemia ; Dyslipidemias - blood ; Dyslipidemias - drug therapy ; Dyslipidemias - physiopathology ; Enrollments ; Evaluation ; Fatalities ; Female ; fimasartan ; Health risks ; Health services ; High density lipoprotein ; Humans ; Hypertension ; Hypertension - blood ; Hypertension - drug therapy ; Hypertension - physiopathology ; Lipids ; Low density lipoprotein ; Male ; Metabolic disorders ; Middle Aged ; Patients ; Physicians ; Pyrimidines - administration & dosage ; Risk ; Risk groups ; rosuvastatin ; Rosuvastatin Calcium - administration & dosage ; Statins ; Synergistic effect ; Tetrazoles - administration & dosage ; Treatment Outcome]]></subject><ispartof>Clinical therapeutics, 2020-06, Vol.42 (6), p.1058-1066.e3</ispartof><rights>2020 The Authors</rights><rights>Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.</rights><rights>2020. The Authors</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c394t-ead5247d39b826a29369bbe397b411ef3467f7f01be28c03b36a2d4dd8279763</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0149291820301867$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65534</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32376036$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lee, Seung-Jun</creatorcontrib><creatorcontrib>Oh, Jaewon</creatorcontrib><creatorcontrib>Hong, Sung-Jin</creatorcontrib><creatorcontrib>Cho, In-Jeong</creatorcontrib><creatorcontrib>Kim, Su Rae</creatorcontrib><creatorcontrib>Uhm, Jae-Sun</creatorcontrib><creatorcontrib>Shim, Chi Young</creatorcontrib><creatorcontrib>Chang, Hyuk-Jae</creatorcontrib><creatorcontrib>Ahn, Chul-Min</creatorcontrib><creatorcontrib>Kim, Jung-Sun</creatorcontrib><creatorcontrib>Kim, Byeong-Keuk</creatorcontrib><creatorcontrib>Park, Sungha</creatorcontrib><creatorcontrib>Lee, Sang-Hak</creatorcontrib><creatorcontrib>Hong, Geu Ru</creatorcontrib><creatorcontrib>Ko, Young-Guk</creatorcontrib><creatorcontrib>Choi, Donghoon</creatorcontrib><title>Effectiveness of Fimasartan and Rosuvastatin Combination Treatment in Hypertensive Patients With Dyslipidemia</title><title>Clinical therapeutics</title><addtitle>Clin Ther</addtitle><description>The goal of this study was to evaluate the concurrent control rate of hypertension and dyslipidemia by fimasartan and rosuvastatin in patients who were concomitantly prescribed both drugs.
: This single-center, cross-sectional study was conducted in 536 patients with hypertension and dyslipidemia who were taking fimasartan and rosuvastatin together for at least 12 weeks. Patients were enrolled from October 2016 to March 2018 at a tertiary hospital in the Republic of Korea. The primary end point was the concurrent control rate of blood pressure (<140/90 mm Hg) and LDL-C. As a secondary end point, the target blood pressure <130/80 mm Hg was adopted in all patients or in high-risk patients with atherosclerotic cardiovascular diseases. Target LDL-C and non–HDL-C levels followed the domestic guidelines. Correlation between blood pressure control and lipid profile was also evaluated. All parameters were assessed in a clinic by board-certified physicians.
Of the total 536 patients, 69% (n = 368) had very high (n = 308) or high (n = 60) cardiovascular risk, with an average age of 65 years; 57% were male. When the target blood pressure was set at 140/90 mm Hg, the proportion of patients meeting the targeting LDL-C level was 40.3% (95% CI, 36.2–44.5; P < 0.001). When applied to the revised blood pressure criteria targeting 130/80 mm Hg, the concurrent control rate dropped by one half to 20.3% (95% CI, 17.2–24.0; P < 0.001). To apply the new blood pressure criteria, more intensive management is mandatory in patients with high or very high cardiovascular risk. There was no positive correlation between the controlled rate of hypertension and dyslipidemia.
Fimasartan and rosuvastatin were shown to have effects on target diseases, but there was no synergistic effect when administered in combination. The higher the cardiovascular risk of the patients, the lower the rate of concurrent control when fimasartan and rosuvastatin were administered simultaneously. More active treatment is therefore required in high-risk patients.</description><subject>Adult</subject><subject>Aged</subject><subject>angiotensin receptor blocker</subject><subject>Anticholesteremic Agents - administration & dosage</subject><subject>Antihypertensive Agents - administration & dosage</subject><subject>Antihypertensives</subject><subject>Arteriosclerosis</subject><subject>Atherosclerosis</subject><subject>Biphenyl Compounds - administration & dosage</subject><subject>Blood pressure</subject><subject>Blood Pressure - drug effects</subject><subject>Cardiovascular disease</subject><subject>Cardiovascular diseases</subject><subject>Cholesterol</subject><subject>Cholesterol, LDL - blood</subject><subject>Clinical medicine</subject><subject>Coronary vessels</subject><subject>Cross-Sectional Studies</subject><subject>Drug dosages</subject><subject>Drug Therapy, Combination</subject><subject>Dyslipidemia</subject><subject>Dyslipidemias - blood</subject><subject>Dyslipidemias - drug therapy</subject><subject>Dyslipidemias - physiopathology</subject><subject>Enrollments</subject><subject>Evaluation</subject><subject>Fatalities</subject><subject>Female</subject><subject>fimasartan</subject><subject>Health risks</subject><subject>Health services</subject><subject>High density lipoprotein</subject><subject>Humans</subject><subject>Hypertension</subject><subject>Hypertension - blood</subject><subject>Hypertension - drug therapy</subject><subject>Hypertension - physiopathology</subject><subject>Lipids</subject><subject>Low density lipoprotein</subject><subject>Male</subject><subject>Metabolic disorders</subject><subject>Middle Aged</subject><subject>Patients</subject><subject>Physicians</subject><subject>Pyrimidines - administration & dosage</subject><subject>Risk</subject><subject>Risk groups</subject><subject>rosuvastatin</subject><subject>Rosuvastatin Calcium - administration & dosage</subject><subject>Statins</subject><subject>Synergistic effect</subject><subject>Tetrazoles - administration & dosage</subject><subject>Treatment Outcome</subject><issn>0149-2918</issn><issn>1879-114X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFkU9rHCEYh6U0NNs0X6EVeullJv5bHY9hkzSFQEtZaG7ijO8QlxndqrOw376GTXPopSdFn_en_B6EPlHSUkLl1a4dJh_KEyTbMsJIS3hLqH6DVrRTuqFUPL5FK0KFbpim3Tl6n_OOEML1mr1D55xxJQmXKzTfjiMMxR8gQM44jvjOzzbbVGzANjj8M-blYHOxxQe8iXPvQ93GgLcJbJkhFFwv7o97SAVCrkH4RwXqeca_fHnCN8c8-b13MHv7AZ2Ndspw-bJeoO3d7XZz3zx8__ptc_3QDFyL0oB1ayaU47rvmLRMc6n7HrhWvaAURi6kGtVIaA-sGwjveYWccK5jSivJL9CXU-w-xd8L5GJmnweYJhsgLtkwrnXHqeK0op__QXdxSaF-zjDB1nKthBSVUidqSDHnBKPZp1pTOhpKzLMQszOvQsyzEEO4qULq5MeX_KWfwb3O_TVQgesTALWPg4dk8lDbG8D5VMUYF_1_H_kDZX2h8A</recordid><startdate>202006</startdate><enddate>202006</enddate><creator>Lee, Seung-Jun</creator><creator>Oh, Jaewon</creator><creator>Hong, Sung-Jin</creator><creator>Cho, In-Jeong</creator><creator>Kim, Su Rae</creator><creator>Uhm, Jae-Sun</creator><creator>Shim, Chi Young</creator><creator>Chang, Hyuk-Jae</creator><creator>Ahn, Chul-Min</creator><creator>Kim, Jung-Sun</creator><creator>Kim, Byeong-Keuk</creator><creator>Park, Sungha</creator><creator>Lee, Sang-Hak</creator><creator>Hong, Geu Ru</creator><creator>Ko, Young-Guk</creator><creator>Choi, Donghoon</creator><general>Elsevier Inc</general><general>Elsevier Limited</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PJZUB</scope><scope>PKEHL</scope><scope>PPXIY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>202006</creationdate><title>Effectiveness of Fimasartan and Rosuvastatin Combination Treatment in Hypertensive Patients With Dyslipidemia</title><author>Lee, Seung-Jun ; Oh, Jaewon ; Hong, Sung-Jin ; Cho, In-Jeong ; Kim, Su Rae ; Uhm, Jae-Sun ; Shim, Chi Young ; Chang, Hyuk-Jae ; Ahn, Chul-Min ; Kim, Jung-Sun ; Kim, Byeong-Keuk ; Park, Sungha ; Lee, Sang-Hak ; Hong, Geu Ru ; Ko, Young-Guk ; Choi, Donghoon</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c394t-ead5247d39b826a29369bbe397b411ef3467f7f01be28c03b36a2d4dd8279763</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Adult</topic><topic>Aged</topic><topic>angiotensin receptor blocker</topic><topic>Anticholesteremic Agents - administration & dosage</topic><topic>Antihypertensive Agents - administration & dosage</topic><topic>Antihypertensives</topic><topic>Arteriosclerosis</topic><topic>Atherosclerosis</topic><topic>Biphenyl Compounds - administration & dosage</topic><topic>Blood pressure</topic><topic>Blood Pressure - drug effects</topic><topic>Cardiovascular disease</topic><topic>Cardiovascular diseases</topic><topic>Cholesterol</topic><topic>Cholesterol, LDL - blood</topic><topic>Clinical medicine</topic><topic>Coronary vessels</topic><topic>Cross-Sectional Studies</topic><topic>Drug dosages</topic><topic>Drug Therapy, Combination</topic><topic>Dyslipidemia</topic><topic>Dyslipidemias - blood</topic><topic>Dyslipidemias - drug therapy</topic><topic>Dyslipidemias - physiopathology</topic><topic>Enrollments</topic><topic>Evaluation</topic><topic>Fatalities</topic><topic>Female</topic><topic>fimasartan</topic><topic>Health risks</topic><topic>Health services</topic><topic>High density lipoprotein</topic><topic>Humans</topic><topic>Hypertension</topic><topic>Hypertension - blood</topic><topic>Hypertension - drug therapy</topic><topic>Hypertension - physiopathology</topic><topic>Lipids</topic><topic>Low density lipoprotein</topic><topic>Male</topic><topic>Metabolic disorders</topic><topic>Middle Aged</topic><topic>Patients</topic><topic>Physicians</topic><topic>Pyrimidines - administration & dosage</topic><topic>Risk</topic><topic>Risk groups</topic><topic>rosuvastatin</topic><topic>Rosuvastatin Calcium - administration & dosage</topic><topic>Statins</topic><topic>Synergistic effect</topic><topic>Tetrazoles - administration & dosage</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lee, Seung-Jun</creatorcontrib><creatorcontrib>Oh, Jaewon</creatorcontrib><creatorcontrib>Hong, Sung-Jin</creatorcontrib><creatorcontrib>Cho, In-Jeong</creatorcontrib><creatorcontrib>Kim, Su Rae</creatorcontrib><creatorcontrib>Uhm, Jae-Sun</creatorcontrib><creatorcontrib>Shim, Chi Young</creatorcontrib><creatorcontrib>Chang, Hyuk-Jae</creatorcontrib><creatorcontrib>Ahn, Chul-Min</creatorcontrib><creatorcontrib>Kim, Jung-Sun</creatorcontrib><creatorcontrib>Kim, Byeong-Keuk</creatorcontrib><creatorcontrib>Park, Sungha</creatorcontrib><creatorcontrib>Lee, Sang-Hak</creatorcontrib><creatorcontrib>Hong, Geu Ru</creatorcontrib><creatorcontrib>Ko, Young-Guk</creatorcontrib><creatorcontrib>Choi, Donghoon</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>ProQuest Health & Medical Research Collection</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Health & Nursing</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lee, Seung-Jun</au><au>Oh, Jaewon</au><au>Hong, Sung-Jin</au><au>Cho, In-Jeong</au><au>Kim, Su Rae</au><au>Uhm, Jae-Sun</au><au>Shim, Chi Young</au><au>Chang, Hyuk-Jae</au><au>Ahn, Chul-Min</au><au>Kim, Jung-Sun</au><au>Kim, Byeong-Keuk</au><au>Park, Sungha</au><au>Lee, Sang-Hak</au><au>Hong, Geu Ru</au><au>Ko, Young-Guk</au><au>Choi, Donghoon</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effectiveness of Fimasartan and Rosuvastatin Combination Treatment in Hypertensive Patients With Dyslipidemia</atitle><jtitle>Clinical therapeutics</jtitle><addtitle>Clin Ther</addtitle><date>2020-06</date><risdate>2020</risdate><volume>42</volume><issue>6</issue><spage>1058</spage><epage>1066.e3</epage><pages>1058-1066.e3</pages><issn>0149-2918</issn><eissn>1879-114X</eissn><abstract>The goal of this study was to evaluate the concurrent control rate of hypertension and dyslipidemia by fimasartan and rosuvastatin in patients who were concomitantly prescribed both drugs.
: This single-center, cross-sectional study was conducted in 536 patients with hypertension and dyslipidemia who were taking fimasartan and rosuvastatin together for at least 12 weeks. Patients were enrolled from October 2016 to March 2018 at a tertiary hospital in the Republic of Korea. The primary end point was the concurrent control rate of blood pressure (<140/90 mm Hg) and LDL-C. As a secondary end point, the target blood pressure <130/80 mm Hg was adopted in all patients or in high-risk patients with atherosclerotic cardiovascular diseases. Target LDL-C and non–HDL-C levels followed the domestic guidelines. Correlation between blood pressure control and lipid profile was also evaluated. All parameters were assessed in a clinic by board-certified physicians.
Of the total 536 patients, 69% (n = 368) had very high (n = 308) or high (n = 60) cardiovascular risk, with an average age of 65 years; 57% were male. When the target blood pressure was set at 140/90 mm Hg, the proportion of patients meeting the targeting LDL-C level was 40.3% (95% CI, 36.2–44.5; P < 0.001). When applied to the revised blood pressure criteria targeting 130/80 mm Hg, the concurrent control rate dropped by one half to 20.3% (95% CI, 17.2–24.0; P < 0.001). To apply the new blood pressure criteria, more intensive management is mandatory in patients with high or very high cardiovascular risk. There was no positive correlation between the controlled rate of hypertension and dyslipidemia.
Fimasartan and rosuvastatin were shown to have effects on target diseases, but there was no synergistic effect when administered in combination. The higher the cardiovascular risk of the patients, the lower the rate of concurrent control when fimasartan and rosuvastatin were administered simultaneously. More active treatment is therefore required in high-risk patients.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>32376036</pmid><doi>10.1016/j.clinthera.2020.03.019</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0149-2918 |
| ispartof | Clinical therapeutics, 2020-06, Vol.42 (6), p.1058-1066.e3 |
| issn | 0149-2918 1879-114X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2399831731 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Adult Aged angiotensin receptor blocker Anticholesteremic Agents - administration & dosage Antihypertensive Agents - administration & dosage Antihypertensives Arteriosclerosis Atherosclerosis Biphenyl Compounds - administration & dosage Blood pressure Blood Pressure - drug effects Cardiovascular disease Cardiovascular diseases Cholesterol Cholesterol, LDL - blood Clinical medicine Coronary vessels Cross-Sectional Studies Drug dosages Drug Therapy, Combination Dyslipidemia Dyslipidemias - blood Dyslipidemias - drug therapy Dyslipidemias - physiopathology Enrollments Evaluation Fatalities Female fimasartan Health risks Health services High density lipoprotein Humans Hypertension Hypertension - blood Hypertension - drug therapy Hypertension - physiopathology Lipids Low density lipoprotein Male Metabolic disorders Middle Aged Patients Physicians Pyrimidines - administration & dosage Risk Risk groups rosuvastatin Rosuvastatin Calcium - administration & dosage Statins Synergistic effect Tetrazoles - administration & dosage Treatment Outcome |
| title | Effectiveness of Fimasartan and Rosuvastatin Combination Treatment in Hypertensive Patients With Dyslipidemia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-19T21%3A03%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effectiveness%20of%20Fimasartan%20and%20Rosuvastatin%20Combination%20Treatment%20in%20Hypertensive%20Patients%20With%20Dyslipidemia&rft.jtitle=Clinical%20therapeutics&rft.au=Lee,%20Seung-Jun&rft.date=2020-06&rft.volume=42&rft.issue=6&rft.spage=1058&rft.epage=1066.e3&rft.pages=1058-1066.e3&rft.issn=0149-2918&rft.eissn=1879-114X&rft_id=info:doi/10.1016/j.clinthera.2020.03.019&rft_dat=%3Cproquest_cross%3E2425657464%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2425657464&rft_id=info:pmid/32376036&rft_els_id=S0149291820301867&rfr_iscdi=true |